Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials.

CONCLUSION: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment resulted in a significantly lower risk of fracture. Romosozumab 210 mg monthly showed the largest gains in BMD, and was generally well tolerated.
PMID: 29424257 [PubMed - as supplied by publisher]

Source: Climacteric - February 9, 2018 Category: Geriatrics Authors: Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J Tags: Climacteric Source Type: research